Zinzino Reports 18% Revenue Growth in Q3 2026, Driven by North America and Central Europe

  • Zinzino's group revenue increased by 18% in Q3 2026 compared to the previous year, reaching SEK 928.2 million.
  • North America saw the most significant growth with a 56% increase in September and 55% in Q3.
  • Central Europe's revenue grew by 19% in Q3, while East Europe experienced a 14% decline.
  • Faun Pharma's external sales increased by 73% in September and 17% in Q3.
  • Year-to-date revenue for January–September 2026 increased by 21% to SEK 2,787.1 million.

Zinzino's strong Q3 2026 performance highlights its ability to capitalize on high-growth markets like North America and Central Europe. The company's strategic focus on expanding its pharmaceutical segment through Faun Pharma could position it for further growth, but it must address regional declines and maintain momentum in key markets. The 21% year-to-date revenue increase underscores its resilience in a competitive direct-selling and healthcare landscape.

Geographic Expansion
How Zinzino will sustain its rapid growth in North America and Central Europe while addressing declines in East Europe.
Pharmaceutical Growth
Whether Faun Pharma's 73% increase in September sales signals a long-term strategic shift for Zinzino.
Market Dynamics
The pace at which Zinzino can expand into high-growth regions like Asia-Pacific and South America.